Cargando…

Novel oral glucose‐lowering drugs are associated with lower risk of all‐cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes

AIMS: To investigate the association of novel oral glucose‐lowering drugs (GLDs), compared with that of insulin, with risk of all‐cause mortality, cardiovascular disease (CVD) and severe hypoglycaemia. METHODS: During 2013 to 2014 all patients with type 2 diabetes in Sweden identified as new users o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nyström, Thomas, Bodegard, Johan, Nathanson, David, Thuresson, Marcus, Norhammar, Anna, Eriksson, Jan W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485030/ https://www.ncbi.nlm.nih.gov/pubmed/28116795 http://dx.doi.org/10.1111/dom.12889

Ejemplares similares

Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE‐TIMI 58 trial: A nationwide observational study
por: Norhammar, Anna, et al.
Publicado: (2019)

Dapagliflozin vs non‐SGLT‐2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLARE‐TIMI 58 trial: A nationwide observational study
por: Norhammar, Anna, et al.
Publicado: (2019)

Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with dipeptidyl peptidase‐4 inhibitor therapy: A multinational observational study
por: Persson, Frederik, et al.
Publicado: (2017)

History of heart failure and chronic kidney disease and risk of all-cause death after COVID-19 during the first three waves of the pandemic in comparison with influenza outbreaks in Sweden: a registry-based, retrospective, case–control study
por: Ritsinger, Viveca, et al.
Publicado: (2023)

Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006–2014
por: Nathanson, David, et al.
Publicado: (2017)

Cardiovascular and Renal Disease Burden in Type 1 Compared With Type 2 Diabetes: A Two-Country Nationwide Observational Study
por: Kristófi, Robin, et al.
Publicado: (2021)

Patients with type 1 and type 2 diabetes hospitalized with COVID-19 in comparison with influenza: mortality and cardiorenal complications assessed by nationwide Swedish registry data
por: Kristófi, Robin, et al.
Publicado: (2022)

IDF2022-0622 Mortality and cardiorenal disease in type 1 and type 2 diabetes after COVID-19 and influenza hospitalization in Sweden
por: Kristófl, R., et al.
Publicado: (2023)

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)
por: Kosiborod, Mikhail, et al.
Publicado: (2017)

Sodium–glucose cotransporter 2 inhibitors compared with other glucose‐lowering drugs in Japan: Subanalyses of the CVD‐REAL 2 Study
por: Kohsaka, Shun, et al.
Publicado: (2020)

Lower cardiorenal risk with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study
por: Birkeland, Kåre I., et al.
Publicado: (2020)

Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data
por: Khunti, Kamlesh, et al.
Publicado: (2021)

Different patterns of second‐line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study
por: Persson, Frederik, et al.
Publicado: (2018)

Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2‐inhibitors versus other glucose‐lowering agents in real‐world clinical practice: Results from the CVD‐REAL study
por: Kosiborod, Mikhail, et al.
Publicado: (2018)

Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used
por: Norwood, Paul, et al.
Publicado: (2017)

Association Between Paradoxical HDL Cholesterol Decrease and Risk of Major Adverse Cardiovascular Events in Patients Initiated on Statin Treatment in a Primary Care Setting
por: Hasvold, Pål, et al.
Publicado: (2015)

How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study
por: Birkeland, Kåre I., et al.
Publicado: (2019)

Insulin Hypoglycæmia
Publicado: (1948)

Meta-Analysis of Sulfonylurea Therapy on Long-Term Risk of Mortality and Cardiovascular Events Compared to Other Oral Glucose-Lowering Treatments
por: Powell, W. Ryan, et al.
Publicado: (2018)

Hospitalization for hypoglycaemia in people with diabetes in Denmark, 1997–2017: Time trends in incidence and HbA(1c) and glucose‐lowering drug use before and after hypoglycaemia
por: Bengtsen, Mads Bisgaard, et al.
Publicado: (2021)

Diabetes, metformin and glucose lowering therapies after myocardial infarction: Insights from the SWEDEHEART registry
por: Ritsinger, Viveca, et al.
Publicado: (2020)

Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries
por: Norhammar, Anna, et al.
Publicado: (2022)

Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study
por: Birkeland, Kåre I., et al.
Publicado: (2020)

Glucose/insulin-glargine/insulin-lispro: Hepatic glycogenosis, hypoglycaemia and acute hepatitis: case report
Publicado: (2021)

Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials
por: Boussageon, Rémy, et al.
Publicado: (2011)

The Insulin:Glucagon Ratio and the Choice of Glucose-Lowering Drugs
por: Kalra, Sanjay, et al.
Publicado: (2016)

Impact of ischaemic heart disease severity and age on risk of cardiovascular outcome in diabetes patients in Sweden: a nationwide observational study
por: Jernberg, Tomas, et al.
Publicado: (2019)

Intensive Glucose-Lowering Therapy Reduces Cardiovascular Disease Events in Veterans Affairs Diabetes Trial Participants With Lower Calcified Coronary Atherosclerosis
por: Reaven, Peter D., et al.
Publicado: (2009)

Prevalence, outcomes and costs of a contemporary, multinational population with heart failure
por: Norhammar, Anna, et al.
Publicado: (2023)

Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7)
por: Pratley, Richard E., et al.
Publicado: (2019)

Admission glucose as a prognostic marker for all-cause mortality and cardiovascular disease
por: Djupsjö, Catarina, et al.
Publicado: (2022)

Elderly Patients with Diabetes Experience a Lower Rate of Nocturnal Hypoglycaemia with Insulin Degludec than with Insulin Glargine: A Meta-Analysis of Phase IIIa Trials
por: Sorli, Christopher, et al.
Publicado: (2013)

Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2
por: Heller, Simon R., et al.
Publicado: (2019)

Mediterranean diet lowers all-cause and cardiovascular mortality for patients with metabolic syndrome
por: Fan, Hongxuan, et al.
Publicado: (2023)

Cinnamon extract lowers glucose, insulin and cholesterol in people with elevated serum glucose
por: Anderson, Richard A., et al.
Publicado: (2015)

Better Medications Adherence Lowers Cardiovascular Events, Stroke, and All-Cause Mortality Risk: A Dose-Response Meta-Analysis
por: Liu, Mengying, et al.
Publicado: (2021)

Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors
por: Scheen, André J.
Publicado: (2018)

Correction: Admission glucose as a prognostic marker for all-cause mortality and cardiovascular disease
por: Djupsjö, Catarina, et al.
Publicado: (2022)

Improved glycaemic control and lower hypoglycaemia risk with reduced prior oral antidiabetes drug therapy in patients with type 2 diabetes treated with insulin glargine 300 U/mL
por: Dailey, George, et al.
Publicado: (2018)

Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals
por: Meloni, Alison R, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_qsrg3jrci39a6ri3lgrcj0p33j